다나졸

용도

• Adjunctive treatment of immune-mediated hemolytic anemia
• Adjunctive treatment of immune-mediated hemolytic anemia (non-regenerative forms)
• Adjunctive treatment of immune-mediated hemolytic anemia or thrombocytopenia
• Adjunctive treatment of immune-mediated hemolytic anemia or thrombocytopenia

투여 방법

가능한 부작용

• Hepatotoxicity (rare but significant in dogs)
• Virilization in females
• Weight gain
• Lethargy
• Edema
• Testicular atrophy
• Hirsutism
• Alopecia
• Vaginitis (reported in humans)

주의사항 및 금기

• Pregnancy (Teratogenic - FDA Category X)
• Nursing/breastfeeding
• Severe cardiac function impairment
• Severe renal function impairment
• Severe hepatic function impairment
• Undiagnosed abnormal vaginal bleeding
• > **Warning**: Danazol is highly teratogenic (FDA Category X) and must not be handled by pregnant women or used in pregnant animals. * Use with extreme caution in patients with pre-existing **hepatic, renal, or cardiac dysfunction**. * **Laboratory Alterations**: May alter thyroid panel results (decreased total T4, increased T3 uptake) without causing true hypothyroidism (free T4 and TSH remain normal). * ALT (SGPT) and AST (SGOT) may increase early in therapy but typically decrease towards baseline later in therapy or after discontinuation.

약물 상호작용

• Cyclosporine: May significantly increase cyclosporine levels
• Insulin: By affecting carbohydrate metabolism, danazol may affect insulin requirements (doses may need to be increased) in diabetic patients
• Warfarin: Concomitant use may enhance the anticoagulant effect as danazol may decrease the synthesis of procoagulant factors in the liver

자주 묻는 질문